SCHEDULE: Vivo Opportunity Discloses DBV Technologies Stake

Vivo Opportunity Fund Holdings and related entities report a combined beneficial ownership of approximately 4.5% in DBV Technologies S.A.

Summary

• Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity Cayman Fund, L.P. filed a Schedule 13G amendment regarding their holdings in DBV Technologies S.A.
• The reporting persons collectively hold 13,337,845 ordinary shares, represented by 2,667,569 American Depository Shares (ADSs).
• Vivo Opportunity Fund Holdings, L.P. holds 11,820,005 shares (4.0% of the class).
• Vivo Opportunity Cayman Fund, L.P. holds 1,517,840 shares (0.5% of the class).
• The ownership percentage is based on 296,042,447 ordinary shares outstanding as of April 30, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory disclosure indicating institutional investment activity without signaling a change in corporate control.

Positives

• The filing confirms that the securities were acquired for investment purposes without the intent to change or influence the control of the issuer.

Negatives

• The reporting entities hold less than 5% of the total outstanding shares, which generally limits their influence on corporate governance compared to major institutional shareholders.

Risks

• The investment is subject to the market volatility of DBV Technologies S.A. shares.
• The value of the investment is dependent on the issuer's ongoing business performance and regulatory outcomes.

Future Outlook

The filing does not provide a forward-looking outlook for the issuer, as it is a disclosure of beneficial ownership by an investment firm.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard regulatory disclosures for investment firms managing passive stakes in biotechnology companies, reflecting ongoing institutional interest in the sector.

Comparison to Industry Standards

• The filing follows standard SEC reporting requirements for institutional investors holding less than 5% of a company's equity.
• The passive investment stance is consistent with typical hedge fund portfolio management strategies for mid-cap biotech firms.

Stakeholder Impact

• Shareholders may view the continued presence of Vivo Opportunity as a sign of institutional confidence in the issuer.

Next Steps

• The reporting persons will continue to monitor their investment in DBV Technologies S.A. in accordance with their investment mandate.

Key Dates

Keywords

DBV Technologies, Schedule 13G, Vivo Opportunity, Beneficial Ownership, ADS, Biotech Investment